Meeder Asset Management’s Solid Biosciences SLDB Stock Holding History

Meeder Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-402	Closed	-$7K	–	2403
2022 Q1	$7K	Buy	+402	New	+$7.09K	﹤0.01%	1696
2021 Q3	–	Sell	-4	Closed	–	–	2622
2021 Q2	$0	Sell	4 -319	-99%	-$21.1K	﹤0.01%	2641
2021 Q1	$27K	Buy	+323	New	+$35.7K	﹤0.01%	1325
2020 Q2	–	Sell	-52	Closed	-$2K	–	2425
2020 Q1	$2K	Buy	+52	New	+$2.57K	﹤0.01%	2115
2019 Q1	–	Sell	-1	Closed	–	–	1837
2018 Q4	$0	Buy	+1	New	+$470	﹤0.01%	1790
2018 Q3	–	Sell	-5	Closed	-$2.46K	–	1680
2018 Q2	$2.46K	Buy	+5	New	+$1.54K	﹤0.01%	1392

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Meeder Asset Management's SLDB Position: Q2 2022 in Review

Meeder Asset Management sold out of Solid Biosciences (SLDB) in Q2 2022, closing a stake of 402 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in SLDB in Q2 2018 and held it in 6 quarters. The position peaked at $27K in Q1 2021. 67 funds tracked by Wall St. Rank hold SLDB as of Q2 2022.

Meeder Asset Management reported no remaining Solid Biosciences position as of Q2 2022 after selling out during the quarter.
Meeder Asset Management sold 402 Solid Biosciences shares in Q2 2022, an estimated $7K.
Meeder Asset Management first reported a position in Solid Biosciences in Q2 2018 and held it in 6 quarters.
Meeder Asset Management's Solid Biosciences position peaked at $27K in Q1 2021.
67 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2022.

Based on Meeder Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.